Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Amgen Wins U.S. Patent Battle on Arthritis Drug Enbrel

Deena Beasley  |  

U.S.-listed shares of Novartis closed down 0.5% at $90.82.

Amgen is also suing Samsung Bioepis over its Enbrel biosimilar. That litigation remains under way, an Amgen spokeswoman said on Friday. Officials at Samsung Bioepis did not immediately respond to a request for comment.

ADVERTISEMENT
SCROLL TO CONTINUE

(Reporting by Deena Beasley in Los Angeles Additional reporting by Jan Wolfe and Ankur Banerjee; editing by Shinjini Ganguli and Leslie Adler)

Related Articles

    Rheumatology Drug Updates

    Information on new approvals and medication safety that rheumatologists need to know

    Cliff Diving: Evergreening & Other Oddities

    The glassblowers were in revolt. The island of Murano, in the 13th century, was a perfect home for the glassblowing industry. Connected to Venice through a system of bridges, Murano was surrounded by waters that protected the city from the furnaces that fueled the glassblowers’ craft. The Republic of Venice dominated trade throughout the Mediterranean,…

    U.S. Tribal Patent Deal Could Impact Generic Drug Market

    (Reuters)—A groundbreaking deal between Allergan Plc. and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts say, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry eye…

    Novartis Biosimilar Takes Aim at Amgen’s Enbrel

    ZURICH (Reuters)—The U.S. Food and Drug Administration has accepted Novartis unit Sandoz’s regulatory submission for approval of a biosimilar copy of Amgen’s blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said on Friday. Enbrel, or etanercept as the drug is known generically, is a big prize since it was the world’s fifth-biggest selling medicine in 2014…